Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.52 |
| ▸ | METAP1 | P53582 | 4/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215028 | 0.82 | CYP19A1 (0.46) | ACHECYP19A1TSHRALDH1A1KDM4E | |
| SCHEMBL9542690 | 0.71 | CREBBP (0.47) | TSHRALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL5539639 | 0.71 | ACHE (0.63) | ACHEMETAP1CYP19A1TSHRS100A4 | |
| SCHEMBL14157895 | 0.71 | ACHE (0.63) | ACHEMETAP1CYP19A1TSHRS100A4 | |
| SCHEMBL9149487 | 0.70 | HTR2A (0.49) | ACHECYP19A1ALDH1A1S100A4KDM4E | |
| SCHEMBL3351414 | 0.70 | SIRT1 (0.39) | ACHETSHRALDH1A1MEN1MAPT | |
| SCHEMBL30069509 | 0.70 | SIRT1 (0.39) | ACHETSHRALDH1A1MEN1MAPT | |
| SCHEMBL11818087 | 0.70 | ACHE (0.61) | ACHEMETAP1CYP19A1TSHRKDM4E | |
| SCHEMBL7939001 | 0.69 | ACHE (0.65) | ACHEMETAP1CYP19A1TSHRKDM4E | |
| SCHEMBL9752693 | 0.68 | ACHE (1.00) | ACHEMETAP1CYP19A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954178-B1 | Synthesis of haloindenes | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2021-03-23 | — | — | US | disclosed |
| US-6858610-B2 | Potassium channel inhibitors | ICAGEN, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-6849634-B2 | Potassium channel inhibitors | ICAGEN (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1345905-A1 | POTASSIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030013706-A1 | Potassium channel inhibitors | ICAGEN | 2003-01-16 | — | — | US | disclosed |
| US-20020161011-A1 | Potassium channel inhibitors | ICAGEN | 2002-10-31 | — | — | US | disclosed |
| US-6458794-B2 | ANTIARRHYTHMIA AGENT, ANTIPROLIFERATIVE AGENT | ICAGEN, INC. | 2002-10-01 | — | — | US | disclosed |
| EP-1240147-A1 | POTASSIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| WO-2002060874-A1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN INCORPORATED (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20020006929-A1 | Potassium channel inhibitors | ICAGEN, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001046155-A1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| US-4569689-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1986-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161011-A1 | Potassium channel inhibitors | KCNN2, KCNN1, KCNN3 | ACHE 4577/4885METAP1 3570/4885CYP19A1 4288/4885 |
| US-20020006929-A1 | Potassium channel inhibitors | KCNN2, KCNN1, KCNN3 | ACHE 4577/4885METAP1 3570/4885CYP19A1 4288/4885 |
| US-20030013706-A1 | Potassium channel inhibitors | KCNN2, KCNN1, KCNN3 | ACHE 4577/4885METAP1 3570/4885CYP19A1 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.